Skoči na glavni sadržaj

Sažetak sa skupa

https://doi.org/10.15836/ccar2021.359

Sestrinski aspekt kod primjene antikoagulantne terapije prije i nakon ablacijskog liječenja fibrilacije atrija

Antonela Barišić orcid id orcid.org/0000-0002-3558-2034 ; Klinički bolnički centar Sestre milosrdnice, Zagreb, Hrvatska
Dominik Tvorek orcid id orcid.org/0000-0001-6909-4197 ; Klinički bolnički centar Sestre milosrdnice, Zagreb, Hrvatska


Puni tekst: hrvatski pdf 142 Kb

str. 359-359

preuzimanja: 123

citiraj

Puni tekst: engleski pdf 142 Kb

str. 359-359

preuzimanja: 92

citiraj

Preuzmi JATS datoteku


Sažetak

Ključne riječi

antikoagulantna terapija; sestrinski aspekt; ablacijsko liječenje

Hrčak ID:

265053

URI

https://hrcak.srce.hr/265053

Datum izdavanja:

6.10.2021.

Podaci na drugim jezicima: engleski

Posjeta: 520 *



Atrial fibrillation (AF) is the most common persistent arrhythmia in the general population, with a prevalence of 2–4% in adulthood and a tendency to increase 2- to 3-fold in terms of life expectancy. (1) AF is the cause of numerous vascular complications, including cerebrovascular stroke (20-30% ischemic stroke or 10% cryptogenic stroke), heart failure due to increased ventricular rate (in 20-30% of FA patients), vascular dementia, and other general disorders such as depression or frequent hospitalizations. (2) The generally accepted treatment for vascular complications is warfarin, and more recently, new oral anticoagulants, which can cause hemorrhage. (3)

The decision on the type of treatment approach is made on the basis of symptoms, type of cardiac treatment (ECG, the holter ECG, echocardiography, blood tests), the physician’s decision and the patient’s consent to the proposed treatment. Catheter atrial fibrillation ablation is an invasive procedure during which controlled local heating or cooling of the tissue is performed to target the source of the arrhythmia. This procedure contributes greatly to the improvement of symptomatology in patients and supports further progress in the treatment of AF. Before performing ablation treatment, it is important to mentally and physically prepare the patient for the procedure. The physical preparation of the patient includes, among other things, TEE (the issue of thrombus in the auricle) and the application of therapy (anticoagulants). It is very important when acquiring a medical history, to acquire information on which anticoagulant drug is used and how long the patient has been using it. (2)

Postprocedural care involves monitoring the cognitive status, the presence of neurological outbursts, monitoring the puncture site, the presence of chest pain, throat, back, blood pressure control, ECG, patient mobilization, and monitoring of complications. When caring for a patient, it is important to mention the holistic approach and the principle of individual approach to each patient. The aim of this lecture is to present the measures implemented in nursing care before and after ablation treatment. It is important to be aware of the connection between anticoagulant therapy and ablation therapy. The nurse as part of a multidisciplinary team has an important role in the prevention of complications, but also in their early detection, which greatly affects the quality of life of patients.

LITERATURE

1 

Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014 February 25;129(8):837–47. https://doi.org/10.1161/CIRCULATIONAHA.113.005119 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24345399

2 

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 February 1;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/32860505

3 

Bernat R. Farmakoterapija fibrilacije atrija. Medicus. 2010;19(2_Kardiologija):203-214. Available at:https://hrcak.srce.hr/65108


This display is generated from NISO JATS XML with jats-html.xsl. The XSLT engine is libxslt.